The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
For approximately three decades, autologous hematopoietic cell transplantation (auto-HCT) has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after frontline therapy. This approach is limited due to the intensity of chemotherapy and the pro...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-12-01
|
Series: | Therapeutic Advances in Hematology |
Online Access: | https://doi.org/10.1177/20406207221141511 |
_version_ | 1811179212505088000 |
---|---|
author | Omar Albanyan Julio Chavez Javier Munoz |
author_facet | Omar Albanyan Julio Chavez Javier Munoz |
author_sort | Omar Albanyan |
collection | DOAJ |
description | For approximately three decades, autologous hematopoietic cell transplantation (auto-HCT) has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after frontline therapy. This approach is limited due to the intensity of chemotherapy and the proportion of patients who relapse after auto-HCT. Since the approval of anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy and novel agents, the treatment paradigm for DLBCL has changed remarkably. Anti-CD19 CAR-T therapy was first approved for relapsed DLBCL after two or more previous lines of therapy with long-lasting responses, with over 50% of patients still alive at 5-year follow-up. Here, we discuss recent randomized phase 3 clinical trials using axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel in the second-line therapy setting compared with the standard of care in transplant-eligible patients who have DLBCL R/R within 12 months of completing chemo-immunotherapy, potentially changing the treatment algorithm for DLBCL. |
first_indexed | 2024-04-11T06:31:04Z |
format | Article |
id | doaj.art-d0f37e1c589a45beb0d82dbb7aa57788 |
institution | Directory Open Access Journal |
issn | 2040-6215 |
language | English |
last_indexed | 2024-04-11T06:31:04Z |
publishDate | 2022-12-01 |
publisher | SAGE Publishing |
record_format | Article |
series | Therapeutic Advances in Hematology |
spelling | doaj.art-d0f37e1c589a45beb0d82dbb7aa577882022-12-22T04:40:03ZengSAGE PublishingTherapeutic Advances in Hematology2040-62152022-12-011310.1177/20406207221141511The role of CAR-T cell therapy as second line in diffuse large B-cell lymphomaOmar AlbanyanJulio ChavezJavier MunozFor approximately three decades, autologous hematopoietic cell transplantation (auto-HCT) has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after frontline therapy. This approach is limited due to the intensity of chemotherapy and the proportion of patients who relapse after auto-HCT. Since the approval of anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy and novel agents, the treatment paradigm for DLBCL has changed remarkably. Anti-CD19 CAR-T therapy was first approved for relapsed DLBCL after two or more previous lines of therapy with long-lasting responses, with over 50% of patients still alive at 5-year follow-up. Here, we discuss recent randomized phase 3 clinical trials using axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel in the second-line therapy setting compared with the standard of care in transplant-eligible patients who have DLBCL R/R within 12 months of completing chemo-immunotherapy, potentially changing the treatment algorithm for DLBCL.https://doi.org/10.1177/20406207221141511 |
spellingShingle | Omar Albanyan Julio Chavez Javier Munoz The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma Therapeutic Advances in Hematology |
title | The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma |
title_full | The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma |
title_fullStr | The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma |
title_full_unstemmed | The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma |
title_short | The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma |
title_sort | role of car t cell therapy as second line in diffuse large b cell lymphoma |
url | https://doi.org/10.1177/20406207221141511 |
work_keys_str_mv | AT omaralbanyan theroleofcartcelltherapyassecondlineindiffuselargebcelllymphoma AT juliochavez theroleofcartcelltherapyassecondlineindiffuselargebcelllymphoma AT javiermunoz theroleofcartcelltherapyassecondlineindiffuselargebcelllymphoma AT omaralbanyan roleofcartcelltherapyassecondlineindiffuselargebcelllymphoma AT juliochavez roleofcartcelltherapyassecondlineindiffuselargebcelllymphoma AT javiermunoz roleofcartcelltherapyassecondlineindiffuselargebcelllymphoma |